Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma

Figure 1 Kaplan-Meier curve of time-to-progression in the surgical resection + sorafenib and surgical resection groups. The median time to progression (TTP) was estimated from the patients with equivalent as 0.5 and derived as 29 mo (95%CI: 26.5-31.5 mo) and 22 mo (95%CI: 18.0-26.0 mo) for surgical resection (SR) + sorafenib and SR groups, respectively. + indicates censored patients. The log-rank test showed a significant difference in the TTP between groups (P = 0.041).

Figure 2 Kaplan-Meier curve of overall survival times in the surgical resection + sorafenib and surgical resection groups. The median overall survival (OS) time was estimated from the patients with equivalent as 0.5 and derived as 37 mo (95%CI: 34.8-39.2 mo) and 30 mo (95%CI: 24.1-36.0 mo) for the surgical resection (SR) + sorafenib and SR groups, respectively. + indicates censored patients. The log-rank test showed a significant difference in the OS times between groups (P = 0.010).